Spinogenix Appoints Harvard Medical School Professor of Neurology Steven E. Arnold, MD, to Scientific Advisory Board

Spinogenix announced the appointment of a renowned Alzheimer’s expert to support its neurodegenerative disease strategy and translational biomarker development. The update is positioned as an R&D/credibility enhancement rather than a near-term clinical or financial catalyst, implying limited immediate price impact.

Analysis

Spinogenix announced the appointment of a renowned Alzheimer’s expert to support its neurodegenerative disease strategy and translational biomarker development. The update is positioned as an R&D/credibility enhancement rather than a near-term clinical or financial catalyst, implying limited immediate price impact.